Apellis Net Debt from 2010 to 2026

APLS Stock

USD 21.75 0.25 1.14%

Apellis Pharmaceuticals Net Debt yearly trend continues to be comparatively stable with very little volatility. Net Debt is likely to outpace its year average in 2026. Net Debt is the total debt of Apellis Pharmaceuticals minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

2014-03-31

Previous Quarter

98.3 M

Current Value

-3.8 M

Quarterly Volatility

198 M

Yuan Drop

Covid

Check Apellis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Apellis Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 48.8 M or Selling General Administrative of 504.4 M, as well as many indicators such as Price To Sales Ratio of 5.53, Dividend Yield of 0.0 or PTB Ratio of 16.25. Apellis financial statements analysis is a perfect complement when working with Apellis Pharmaceuticals Valuation or Volatility modules.

Build AI portfolio with Apellis Stock

Check out the analysis of Apellis Pharmaceuticals Correlation against competitors.

For more information on how to buy Apellis Stock please use our How to Invest in Apellis Pharmaceuticals guide.

Latest Apellis Pharmaceuticals' Net Debt Growth Pattern

Below is the plot of the Net Debt of Apellis Pharmaceuticals over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Apellis Pharmaceuticals' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Apellis Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Net Debt

Timeline

Apellis Net Debt Regression Statistics

	Arithmetic Mean	(101,052,998)
	Geometric Mean	48,094,624
	Coefficient Of Variation	(154.73)
	Mean Deviation	127,461,405
	Median	(24,863,488)
	Standard Deviation	156,354,950
	Sample Variance	24446.9T
	Range	497.6M
	R-Value	(0.25)
	Mean Square Error	24432.9T
	R-Squared	0.06
	Significance	0.33
	Slope	(7,773,795)
	Total Sum of Squares	391149.9T

Apellis Net Debt History

	2026	55.3 M
	2025	52.6 M
	2024	58.5 M
	2023	-240.3 M
	2022	-439.1 M
	2021	-430 M
	2020	-188 M

Other Fundumenentals of Apellis Pharmaceuticals

Net Debt To E B I T D A

Apellis Pharmaceuticals Net Debt component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Common Stock	Net Tangible Assets	Property Plant Equipment	Capital Surpluse	Long Term Debt	Long Term Debt Total	Net Invested Capital	Short Long Term Debt	Net Working Capital	Short Term Debt	Capital Stock	Current Deferred Revenue	Short Term Investments
Total Assets		0.92	-0.3	-0.9	0.86	0.77	0.99	1.0	0.96	0.89	0.95	0.93	0.85	0.95	0.85	-0.88	0.96	-0.83	0.89	-0.78	-0.83
Total Stockholder Equity	0.92		-0.23	-0.85	0.85	0.76	0.87	0.92	0.94	0.96	0.8	0.89	0.79	0.79	0.82	-0.82	0.83	-0.77	0.82	-0.77	-0.79
Net Debt	-0.3	-0.23		0.18	-0.11	0.27	-0.31	-0.33	-0.28	-0.42	-0.43	-0.4	0.21	-0.33	0.22	0.44	-0.36	0.46	-0.2	-0.07	0.23
Retained Earnings	-0.9	-0.85	0.18		-0.97	-0.86	-0.89	-0.89	-0.95	-0.77	-0.89	-0.83	-0.75	-0.88	-0.78	0.79	-0.81	0.71	-0.97	0.83	0.97
Accounts Payable	0.86	0.85	-0.11	-0.97		0.88	0.84	0.85	0.94	0.75	0.8	0.82	0.76	0.83	0.78	-0.76	0.73	-0.69	0.94	-0.89	-0.95
Net Receivables	0.77	0.76	0.27	-0.86	0.88		0.74	0.74	0.82	0.61	0.66	0.68	0.86	0.73	0.88	-0.59	0.63	-0.52	0.83	-0.89	-0.82
Total Liab	0.99	0.87	-0.31	-0.89	0.84	0.74		0.99	0.93	0.84	0.96	0.92	0.84	0.97	0.83	-0.87	0.96	-0.82	0.88	-0.76	-0.82
Total Current Assets	1.0	0.92	-0.33	-0.89	0.85	0.74	0.99		0.95	0.89	0.95	0.94	0.83	0.95	0.83	-0.88	0.96	-0.84	0.88	-0.76	-0.82
Common Stock	0.96	0.94	-0.28	-0.95	0.94	0.82	0.93	0.95		0.9	0.9	0.95	0.8	0.92	0.8	-0.89	0.85	-0.84	0.92	-0.84	-0.89
Net Tangible Assets	0.89	0.96	-0.42	-0.77	0.75	0.61	0.84	0.89	0.9		0.79	0.91	0.67	0.77	0.69	-0.85	0.81	-0.82	0.75	-0.63	-0.7
Property Plant Equipment	0.95	0.8	-0.43	-0.89	0.8	0.66	0.96	0.95	0.9	0.79		0.9	0.72	0.96	0.71	-0.87	0.96	-0.82	0.91	-0.64	-0.82
Capital Surpluse	0.93	0.89	-0.4	-0.83	0.82	0.68	0.92	0.94	0.95	0.91	0.9		0.74	0.93	0.72	-0.96	0.84	-0.94	0.8	-0.69	-0.75
Long Term Debt	0.85	0.79	0.21	-0.75	0.76	0.86	0.84	0.83	0.8	0.67	0.72	0.74		0.8	0.99	-0.66	0.78	-0.61	0.74	-0.8	-0.66
Long Term Debt Total	0.95	0.79	-0.33	-0.88	0.83	0.73	0.97	0.95	0.92	0.77	0.96	0.93	0.8		0.76	-0.88	0.9	-0.84	0.86	-0.74	-0.8
Net Invested Capital	0.85	0.82	0.22	-0.78	0.78	0.88	0.83	0.83	0.8	0.69	0.71	0.72	0.99	0.76		-0.63	0.79	-0.58	0.77	-0.84	-0.7
Short Long Term Debt	-0.88	-0.82	0.44	0.79	-0.76	-0.59	-0.87	-0.88	-0.89	-0.85	-0.87	-0.96	-0.66	-0.88	-0.63		-0.81	0.99	-0.75	0.59	0.7
Net Working Capital	0.96	0.83	-0.36	-0.81	0.73	0.63	0.96	0.96	0.85	0.81	0.96	0.84	0.78	0.9	0.79	-0.81		-0.77	0.85	-0.63	-0.74
Short Term Debt	-0.83	-0.77	0.46	0.71	-0.69	-0.52	-0.82	-0.84	-0.84	-0.82	-0.82	-0.94	-0.61	-0.84	-0.58	0.99	-0.77		-0.68	0.52	0.61
Capital Stock	0.89	0.82	-0.2	-0.97	0.94	0.83	0.88	0.88	0.92	0.75	0.91	0.8	0.74	0.86	0.77	-0.75	0.85	-0.68		-0.8	-0.95
Current Deferred Revenue	-0.78	-0.77	-0.07	0.83	-0.89	-0.89	-0.76	-0.76	-0.84	-0.63	-0.64	-0.69	-0.8	-0.74	-0.84	0.59	-0.63	0.52	-0.8		0.86
Short Term Investments	-0.83	-0.79	0.23	0.97	-0.95	-0.82	-0.82	-0.82	-0.89	-0.7	-0.82	-0.75	-0.66	-0.8	-0.7	0.7	-0.74	0.61	-0.95	0.86

Click cells to compare fundamentals

About Apellis Pharmaceuticals Financial Statements

Apellis Pharmaceuticals shareholders use historical fundamental indicators, such as Net Debt, to determine how well the company is positioned to perform in the future. Although Apellis Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Apellis Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Apellis Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Net Debt	52.6 M	55.3 M
Net Debt To EBITDA	(0.34)	(0.36)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Apellis Stock Analysis

When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Apellis Net Debt from 2010 to 2026

Latest Apellis Pharmaceuticals' Net Debt Growth Pattern

Apellis Net Debt Regression Statistics

Apellis Net Debt History

Other Fundumenentals of Apellis Pharmaceuticals

Apellis Pharmaceuticals Net Debt component correlations

About Apellis Pharmaceuticals Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Apellis Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY